This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to a new study. According to the researchers, these risk reductions are likely driven by the replacement of red and processed meats with plant proteins. The researchers also observed that a combination of consuming more plant protein and higher protein intake overall provided the most heart health benefits.
Greetings! In case you missed it, here are all of the studies I covered in the November 2024 installments of the Physiology Friday newsletter. Enjoy (or re-enjoy) these summaries, and don’t forget to share them with someone you think might learn from or be interested in them. Thanks for reading! Physiologically Speaking is a reader-supported publication.
A cancer therapy that prompts the body's immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the heart's largest blood vessels, a new study suggests.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
A critical review of cell-based and cell product-based therapies for the treatment of heart failure details 20 years of completed and ongoing clinical trials. While none has yet gained medical approval, pathways to new treatments for heart failure can take decades, as seen for two other, now accepted therapies.
Salt Lake City-based Intermountain Health's St. Mary's Regional Hospital in Grand Junction, Colo., has become the first community hospital in the nation to receive vascular verification from the American College of Surgeons and the Society for Vascular Surgery.
Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to a new study led by researchers at Harvard T.H. Chan School of Public Health. According to the researchers, these risk reductions are likely driven by the replacement of red and processed meats with plant proteins.
Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to a new study led by researchers at Harvard T.H. Chan School of Public Health. According to the researchers, these risk reductions are likely driven by the replacement of red and processed meats with plant proteins.
Metabolic dysfunction–associated steatotic hepatitis (MASH) is a chronic progressive liver disease that is highly prevalent worldwide. MASH is characterized by hepatic steatosis, inflammation, fibrosis, and liver damage, which eventually result in liver dysfunction due to cirrhosis or hepatocellular carcinoma. However, the cellular and molecular mechanisms underlying MASH progression remain largely unknown.
A cancer therapy that prompts the body's immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the heart's largest blood vessels, a new study suggests.
Between 2% to 3% of all patients and 5% to 6% of all women who present with what looks like an acute coronary syndrome (ACS) are actually suffering from a peculiar and reversible acute cardiac condition, not caused by epicardial coronary obstruction, called takotsubo syndrome (TTS).
Stress after a heart attack is understandableand new research into what drives such stress suggests that fear of another heart attack might play a significant role.
Measuring your blood pressure at home means you can take readings over several days to get a better picture of your health, instead of one-off measurements at the doctor's clinic.
What is the ability of commercially available waist-high compression (WHC) garments to reduce heart rate and improve symptoms in patients with postural orthostatic tachycardia syndrome (POTS) in a community setting?
With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and Zepbound can address outcomes in cardiovascular health.
Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.
I do not want to be a lab rat. This is what a patient who self-identified as Black told me when I attempted to obtain his approval to discuss his case and allow a physical examination during our fellowship weekly bedside teaching rounds.
As announced by NovelMed on December 2, 2024, the FDA has granted IND clearance for Ruxoprubart to commence an efficacy trial for the treatment of IgAN.
Current guidelines regarding beta-blocker use after myocardial infarction (MI) recommend against continuation to improve outcomes after 1 year, in the absence of reduced left ventricular ejection fraction (LVEF; <50%) or other primary indications for therapy.
These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.
Cardiovascular medicine is at a crossroads, navigating the dual pressures of an aging population and an evolving health care landscape. The business of cardiology, in particular, is being reshaped by a myriad of cultural and technological trends.
The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.
For 75 years, the ACC has led in providing cutting-edge, innovative education to cardiovascular clinicians, ensuring they have the latest knowledge and skills to optimize patient care and outcomes. This month, Cardiology highlights three examples of ACC Education in action.
People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.
Bob Ross, PA-C, shares expert insights on early PAD detection, updated guidelines, and practical tools to improve vascular health outcomes from CAPP 2024.
The transmissible nature of prion diseases enables reproduction of neurodegeneration in small animal models that faithfully follows the disease process observed in the natural disease of animals and humans. This allows the temporal development of disease to be investigated and correlated with pathology in a complex brain environment. In this issue of the JCI, Makarava et al. describe a shift in microglia morphology from an active phagocytic phenotype to a passive association with neuronal cell b
Panelists discuss how misdiagnosis and delayed diagnosis of IgA nephropathy occur, highlighting the primary barriers to timely detection and strategies to overcome these challenges.
The cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING) pathway is a critical driver of type I interferon (IFN-I) and antitumor CD8+ T cell responses after radiotherapy (RT). In this issue of the JCI, two reports describe mechanisms that restrained STING signaling and abrogated antitumor immunity after RT. Wen, Wang, and colleagues discovered that IFN-I mediated the induction of YTHDF1, an RNA N6-methyladenosine–binding protein, in DCs after RT promoted cathepsin-mediated STING d
Upon RNA virus infection, the signaling adaptor MAVS forms functional prion-like aggregates on the mitochondrial outer membrane, which serve as a central hub that links virus recognition to downstream antiviral innate immune responses. Multiple mechanisms regulating MAVS activation have been revealed; however, the checkpoint governing MAVS aggregation remains elusive.
Panelists discuss how SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, along with strategies for managing hyperkalemia in patients to help them resume their treatment course.
Work, practice, expense and liability relative value units (RVUs) are updated annually through the Centers for Medicare and Medicaid Services' Medicare Physician Fee Schedule (PFS) rulemaking.
Panelists discuss how clinicians can differentiate IgA nephropathy from other glomerular diseases, such as lupus nephritis and membranous nephropathy, that may present with similar clinical features.
The Centers for Medicare and Medicaid Services (CMS) released the 2025 Medicare Physician Fee Schedule (PFS) final rule on Nov. 1. Of note, the 2025 PFS conversion factor is $32.3465, a reduction of 2.83% from $33.2875 in 2024.
Hypertension, Ahead of Print. BACKGROUND:Aldosterone-producing adenomas (APAs) are a common cause of primary aldosteronism that can lead to cardiovascular complications if left untreated. Machine learning-based bioinformatics approaches have emerged as powerful tools for identifying potential disease markers, gaining widespread recognition in biomedical research.
Critical care cardiology (CCC) requires specialized and advanced training. A comprehensive guide for current trainees, along with insights about the present landscape of CCC, as well as issues to be addressed for continued advancement were the focus of a recent JACC Scientific Expert Panel.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
112 
Let's personalize your content